Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.
The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control.
The granted U.S. patents are numbered: 11,083,903; 11,110,283; 11,116,985; 11,123,569; 11,213,675; 11,260,236; 11,389,659; and D952,859. The allowed U.S. patent applications are numbered: 16/547,324; 16/871,738; 16/913,532; and 16/882,295.
“Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” said Raymond W. Cohen, chief executive officer.
